Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
June 07, 2018 07:00 ET
|
Zafgen, Inc.
BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer
May 30, 2018 07:00 ET
|
Zafgen, Inc.
BOSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
Zafgen Reports First Quarter 2018 Operating and Financial Results
May 08, 2018 16:05 ET
|
Zafgen, Inc.
Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association (ADA) Scientific Sessions ZGN-1061 Phase 1 SAD / MAD data published in Diabetes, Obesity and Metabolism...
Zafgen to Present at Deutsche Bank 43rd Annual Health Care Conference
May 02, 2018 16:30 ET
|
Zafgen, Inc.
BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results
May 01, 2018 16:30 ET
|
Zafgen, Inc.
BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Present at Cowen 38th Annual Health Care Conference
March 07, 2018 16:30 ET
|
Zafgen, Inc.
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
March 06, 2018 16:05 ET
|
Zafgen, Inc.
ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and placebo-like side effect profile ZGN-1061 interim efficacy data indicate significant A1C lowering vs. placebo...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results
March 01, 2018 16:30 ET
|
Zafgen, Inc.
BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 08, 2018 16:00 ET
|
Zafgen, Inc.
BOSTON, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018
January 05, 2018 07:00 ET
|
Zafgen, Inc.
ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as...